Equillium Inc.

6.83+0.1000+1.49%Vol 34.37K1Y Perf 19.98%
Sep 23rd, 2021 12:53 DELAYED
BID6.76 ASK6.88
Open6.62 Previous Close6.73
Pre-Market- After-Market-
 - -%  - -
Target Price
14.00 
Analyst Rating
Strong Buy 1.00
Potential %
104.98 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
42.75 
Earnings Rating
Buy
Market Cap200.69M 
Earnings Date
9th Nov 2021
Alpha0.00 Standard Deviation0.44
Beta1.61 

Today's Price Range

6.466.83

52W Range

3.4711.33

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
13.49%
1 Month
9.61%
3 Months
12.54%
6 Months
-10.27%
1 Year
19.98%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EQ6.830.10001.49
AAPL146.690.84000.58
GOOG2 838.0419.27000.68
MSFT299.711.13000.38
XOM57.061.85003.35
WFC48.091.01002.15
JNJ165.551.62000.99
FB346.072.86000.83
GE103.905.36005.44
JPM161.395.48003.51
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.31-0.310.00
Q01 2021-0.34-0.332.94
Q04 2020-0.38-0.365.26
Q03 2020-0.41-0.3124.39
Q02 2020-0.44-0.3715.91
Q01 2020-0.42-0.45-7.14
Q04 2019-0.40-0.44-10.00
Q03 2019-0.36-0.352.78
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.340.00-
12/2021 QR-0.33-3.13Negative
12/2021 FY-1.290.77Positive
12/2022 FY-1.492.61Positive
Next Report Date9th Nov 2021
Estimated EPS Next Report-0.34
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume34.37K
Shares Outstanding29.38M
Shares Float16.15M
Trades Count275
Dollar Volume2.11M
Avg. Volume251.87K
Avg. Weekly Volume87.49K
Avg. Monthly Volume123.16K
Avg. Quarterly Volume115.31K

Equillium Inc. (NASDAQ: EQ) stock closed at 6.73 per share at the end of the most recent trading day (a 3.22% change compared to the prior day closing price) with a volume of 136.26K shares and market capitalization of 200.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Equillium Inc. CEO is Bruce D. Steel.

The one-year performance of Equillium Inc. stock is 19.98%, while year-to-date (YTD) performance is 25.79%. EQ stock has a five-year performance of %. Its 52-week range is between 3.47 and 11.33, which gives EQ stock a 52-week price range ratio of 42.75%

Equillium Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 2.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.94%, a ROC of -48.29% and a ROE of -57.32%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Equillium Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Equillium Inc.’s next earnings report date is 09th Nov 2021.

The consensus rating of Wall Street analysts for Equillium Inc. is Strong Buy (1), with a target price of $14, which is +104.98% compared to the current price. The earnings rating for Equillium Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Equillium Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Equillium Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.57, ATR14 : 0.45, CCI20 : 160.71, Chaikin Money Flow : 0.17, MACD : 0.13, Money Flow Index : 56.35, ROC : 11.79, RSI : 61.57, STOCH (14,3) : 90.38, STOCH RSI : 1.00, UO : 69.80, Williams %R : -9.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Equillium Inc. in the last 12-months were: Jason A. Keyes (Sold 18 000 shares of value $98 982 ), Stephen Connelly (Option Excercise at a value of $191 266), Stephen Connelly (Sold 96 424 shares of value $583 010 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Equillium Inc.

Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.

CEO: Bruce D. Steel

Telephone: +1 858 412-5302

Address: 2223 Avenida De La Playa, La Jolla 92037, CA, US

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

47%53%

Bearish Bullish

48%52%

TipRanks News for EQ

Wed, 11 Aug 2021 10:35 GMT Equillium (EQ) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 10 Aug 2021 21:25 GMT Equillium (EQ) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits